Investigational drugs targeting FLT3 for leukemia. - Wikidata - wikimedia - TriplyDB

Investigational drugs targeting FLT3 for leukemia.

Investigational drugs targeting FLT3 for leukemia.

http://www.wikidata.org/entity/Q37577934

about

Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML

P2860

Q34805329-769CD2AE-EE66-4342-BBF4-370390CE2132 Q35739494-0D8832A2-51FB-4CA2-87FE-52D3FEEBFE8D

P2860

Investigational drugs targeting FLT3 for leukemia.

http://www.wikidata.org/entity/Q37577934

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Investigational drugs targeting FLT3 for leukemia.

@en

Investigational drugs targeting FLT3 for leukemia.

@nl

type

label

Investigational drugs targeting FLT3 for leukemia.

@en

Investigational drugs targeting FLT3 for leukemia.

@nl

prefLabel

Investigational drugs targeting FLT3 for leukemia.

@en

Investigational drugs targeting FLT3 for leukemia.

@nl

P1433

Q37577934-CD884E39-69E1-4565-8A36-729FB5F653C3

P1476

Q37577934-BD19DEBE-AFDC-4230-9204-1CE8F3D132AF

P2093

Q37577934-3C3014F2-1250-4F58-A192-17FEA1D5DA5D

Q37577934-B2E17D70-B66E-4C65-9968-BC0B666BA6A9

Q37577934-C42CDEC4-A736-4A49-9F73-2B29553AA2B1

Q37577934-DD05466F-6232-4C8C-9A82-1C4888181EEF

P2860

Q37577934-00291CD1-FDD8-4827-AAFC-83FC5452DE10

Q37577934-0128E953-0994-4C77-B920-A420979C18C3

Q37577934-0509F3A0-D3C8-45EB-B9C8-512922908B0A

Q37577934-085739A0-D9DA-4761-921E-0C1591CF028C

Q37577934-095A4FE1-A164-4022-B7F6-C881CAA17043

Q37577934-0A2A5AF7-E4E8-47D4-9FC8-876A7433B9BE

Q37577934-113B5823-771C-4E81-B0CF-C2400E23AA09

Q37577934-12C85C11-676A-4609-AC8B-73CB680E9128

Q37577934-15E4B786-F1AE-49C3-8484-62F14C3848D9

Q37577934-212A14AE-95C6-4F8C-9210-F45C807C8675

P304

Q37577934-9872F46D-7AB5-4E3B-B5D6-73E92AD5554E

P31

Q37577934-35D7812C-8B36-476E-8D2E-B0209FC3B0BE

P356

Q37577934-8B3952C8-A5B8-4F7B-82B7-579194E00B62

P407

Q37577934-434CEE7D-4892-4740-BC16-A05B637B433C

P433

Q37577934-066EA4D9-D06F-4CEC-96DA-94BE68D795A8

P478

Q37577934-B7E874EB-CFA3-4095-9FC1-160A017B94EA

P577

Q37577934-78A7F59D-58D5-495A-B979-B81F920947A1

P698

Q37577934-3D4E7CAC-9CAB-4A7A-A95F-F7D08451D36A

P921

Q37577934-6316B2EC-AAFE-468A-AEA6-CE93D3A04BEE

P356

13543780903179278

P1433

Expert Opinion on Investigational Drugs

P1476

Investigational drugs targeting FLT3 for leukemia.

@en

P2093

Anand P Jillella

http://www.w3.org/2001/XMLSchema#string

Celalettin Ustun

http://www.w3.org/2001/XMLSchema#string

David L DeRemer

http://www.w3.org/2001/XMLSchema#string

Kapil N Bhalla

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs

The role of FLT3 in haematopoietic malignancies

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

P304

1445-1456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543780903179278

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19671038

http://www.w3.org/2001/XMLSchema#string

P921